Reach52 (formally Allied World Healthcare) radically transforms service delivery models for primary care services in
rural and remote areas of LMICs using a digital public health approach. We partner with governments, multi-laterals
and non-profits to make healthcare solutions go further into communities where access is low to non-existent. We
are headquartered in Singapore, with active projects in both Cambodia and Philippines. In the 3 years since our
inception, we have engaged more than 170,000 residents and 1,000 health care workers (HCWs) in dozens of
partner-communities. Our solutions have won numerous awards across Asia, including Singtel Future Makers,
Facebook’s Startup Station, Accenture Health Innovation Challenge (Asia), United Nations World Summit Award
(Singapore), and DBS Foundation Social Enterprise Awardee. We have formal partnerships to implement
access-oriented programs for major multinational pharmaceutical companies and distributers such as Novartis,
Gilead, Sandoz, and Zuellig Pharma.
Reach52 is currently in the planning phases of a project in Western Visayas, Philippines to provide health care worker
training, as well as community screening, diagnostic, and treatment services for hepatitis B virus (HBV). This project is
targeted at low-income residents in rural and remote areas who currently lack access to HBV services due to financial
or geographic barriers. The guidelines adapted for this project are designed to be implemented in a low-resource
setting, and include draft protocols recently developed by the hepatology society of Philippines. Screening and
diagnosis will be conducted through a combination of rapid diagnostic tests and dried blood spot samples. Task
shifting will be employed to provide improved access to treatment initiation and monitoring in community settings.
Tenofovir will be made available at rates below current retail prices. The project will be implemented in cooperation of
our network of peer workers and coordinated through use of our proprietary digital health platform. This initial phase of
the project is designed to screen 10,000 residents for HBsAg seropositivity and will be expanded in the future based on
results. The project is being run in cooperation with a broad range of local stakeholders, including rural health units,
through financial support from Gilead Pharmaceutical.